Search Result

Results for "

Carbapenem-resistant

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (6) Bacterial (17) Beta-lactamase (7) Melanocortin Receptor (2) Oxytocin Receptor (1) Toll-like Receptor (TLR) (1) Vasopressin Receptor (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Endocrinology (1) Infection (20) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147429

Zosurabalpin Abx MCP; RG6006	Antibiotic Bacterial	Infection
Zosurabalpin is a polypeptide antibiotic targeting LPS transporter (LptB₂FGC complex), which can block the transport of LPS and lead to endotoxin accumulation in cells, and has shown excellent antibacterial activity against Carbapenem-resistant Acinetobacter baumanni (CRAB) .

HY-147349

Pilabactam sodium ANT3310 sodium	Beta-lactamase Bacterial	Infection
Pilabactam (ANT3310) sodium is a broad-spectrum covalent Serine β-Lactamase inhibitor, with IC₅₀ values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). Pilabactam sodium potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam sodium can be used in the research of bacterial infection .

HY-P1726

MSG606	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 can delay pain hypersensitivity and reduce cholesterol levels. MSG606 can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-16955A

Plazomicin sulfate 1 Publications Verification ACHN 490 sulfate	Antibiotic Bacterial	Infection
Plazomicin (ACHN 490) sulfate is a semi-synthetic aminoglycoside Antibiotic. Plazomicin sulfate acts as a substrate for Aminoglycoside acetyltransferase and Aminoglycoside phosphotransferase. Plazomicin sulfaten is not modified by various common aminoglycoside-modifying enzymes. Plazomicin sulfate selectively inhibits MATE2-K. Plazomicin sulfate exhibits activity against multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales .

HY-125604

WCK-4234	Beta-lactamase Bacterial	Infection Inflammation/Immunology
WCK-4234 is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 lacks direct antibacterial activity. WCK-4234 inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections .

HY-16955

Plazomicin ACHN 490	Antibiotic Bacterial	Infection Inflammation/Immunology
Plazomicin (ACHN 490) is a semi-synthetic aminoglycoside Antibiotic. Plazomicin acts as a substrate for Aminoglycoside acetyltransferase and Aminoglycoside phosphotransferase. Plazomicin is not modified by various common aminoglycoside-modifying enzymes. Plazomicin selectively inhibits MATE2-K. Plazomicin exhibits activity against multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales .

HY-125416

Streptothricin F	Antibiotic Bacterial	Infection
Streptothricin F is a bactericidal antibiotic. Streptothricin F interacts with the 30S subunit of 70S ribosome. Streptothricin F shows rapid, bactericidal activity against highly drug-resistant, carbapenem-resistant Enterobacterales (CRE) (MIC₅₀ and MIC₉₀: 2 and 4 μM, respectively) and Acinetobacter baumannii .

HY-147349A

Pilabactam ANT3310	Bacterial Beta-lactamase	Infection
Pilabactam (ANT3310) is a broad-spectrum covalent Serine β-Lactamase inhibitor, with IC₅₀ values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). Pilabactam potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam can be used in the research of bacterial infection .

HY-W127616A

β-Sitosterol acetate, 95% Sitosteryl acetate, 95%	Bacterial	Infection
β-Sitosterol acetate, 95% (Sitosteryl acetate, 95%) is a sterol that can be isolated from Hechtia glomerata Zucc., which has antibacterial activity and has a MIC value of 100µg/mL against carbapenem-resistant Acinetobacter baumannii .

HY-178976

YL6113	Beta-lactamase	Infection
YL6113 is a potent and selective dual inhibitor of metallo-β-lactamases (MBLs) and serine-β-lactamases (SBLs). YL6113 shows inhibitory effect to MBLs, such as NDm-1, VIM-2, IMP-1, with IC₅₀ values of 0.25, 27.16 and 3.55 μM. YL6113 shows inhibitory effect to SBLs, such as KPC-2, AmpC, OXA-48, with IC₅₀ values of 0.2, 34.1 and 1.31 μM. YL6113 enhances the antibacterial efficacy of Meropenem (HY-13678) against carbapenem-resistant Gram-negative bacteria. YL6113 can be used for the research of infection .

HY-P0077

Merotocin	Oxytocin Receptor	Endocrinology
Merotocin is a selective, short-acting peptidic oxytocin receptor agonist. Merotocin can be used to support lactation .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-174980

KPC-2-IN-3	Bacterial	Infection
KPC-2-IN-3 (Compound 3b) is a KPC-2 inhibitor with IC₅₀ of 0.533  μM and K_iof 0.194  μM. KPC-2-IN-3 has an antimicrobial activity against carbapenem-resistant K. pneumonia K47-25 and reduces bacterial count with a postantibiotic effect in synergy with Meropenem (HY-13678). KPC-2-IN-3 significantly reduces lung bacterial load in a murine pneumonia model .

HY-P5691

P1	Bacterial	Infection Cancer
P1 is a broad-spectrum antimicrobial peptide. P1 shows antibacterial activity against Gram-positive and Gram-negative bacteria,such as B. anthracis spores and Carbapenem-resistant A. baumannii and K. pneumoniae .

HY-178384

Antibacterial agent 294	Bacterial	Infection
Antibacterial agent 294 is an antibacterial agent. Antibacterial agent 294 shows antibacterial effect against carbapenem-resistant Acinetobacter baumannii (CRAB) with a MIC of 0.5 μg/mL. Antibacterial agent 294 can be used for the research of infection .

HY-142619

TP0586352	Bacterial	Infection
TP0586352 is a LpxC inhibitor that is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk. TP0586352 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150260

SA09-Cu	Bacterial	Infection
SA09-Cu is a noncompetitive and potent NDM-1 inhibitor with an IC₅₀ of 9.6 nM. SA09-Cu can convert NDM-1 into an inactive state by oxidizing the Zn(II)-thiolate site of the enzyme and avoids to be reduced by intracellular thiols of bacteria. SA09-Cu exhibits excellent inhibition against a series of clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae (CRE) in restoring the Meropenem (HY-13678) effect, and slows down the development of carbapenem resistance .

HY-P2331

Actagardin Antibiotic A 3802-IV-3; Gardimycin	Antibiotic	Infection
Actagardin is a tetracyclic lantibiotic produced by several species of Actinoplanes. It is composed of macrocyclic rings formed by thioether bridges. Actagardin preferably targets Gram-positive bacteria, inhibiting the synthesis of peptidoglycan.

HY-P0041

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P11720

M104 peptide	Beta-lactamase Bacterial	Infection
M104 peptide is an OXA-48 carbapenemase inhibitor and antibiotic potentiator. M104 peptide effectively blocks the binding and active site cavity of OXA-48 . M104 peptide restores Meropenem (HY-13678)’s antibacterial activity against OXA-48-producing Klebsiella pneumoniae. M104 peptide can be used for the research of Carbapenem-resistant Klebsiella pneumoniae infection .

HY-125604A

WCK-4234 free base	Beta-lactamase Bacterial	Infection Inflammation/Immunology
WCK-4234 free base is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 free base lacks direct antibacterial activity. WCK-4234 free base inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 free base can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections .

HY-174852

Antibacterial agent 285	Antibiotic Bacterial	Infection
Antibacterial agent 285 (Compound 3) is a cephalosporin antibiotic. Antibacterial agent 285 has significant antibacterial activity against gram-negative bacterium with MICs of 0.125-0.5, 0.125-0.5 and 0.125-2 μg/mL for carbapenem-resistant Acinetobacter baumannii (CRAB), Klebsiella pneumoniae (CRE) and Pseudomonas aeruginosa (CRPA), respectively. Antibacterial agent 285 can be used for bacterial infection research, such as complicated urinary tract infections (cUTI) and kidney infections .

HY-P11580

Pap12-6-10	Toll-like Receptor (TLR) Bacterial	Infection
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize bacterial cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections .

HY-182058

ATM potentiator-1	Beta-lactamase	Infection
ATM potentiator-1 (compound 9) is a β-lactamase inhibitor and efflux pump inhibitor, with an IC₅₀ of 1.6 μM against NDM-1, IC₅₀ values of 12.5 μM and 5.4 μM against OXA-10, an IC₅₀ of 5.0 μM against VIM-2, an IC₅₀ of 26.7 μM against KPC-2, and an IC₅₀ of 3.4 μM against OXA-48. ATM potentiator-1 inhibits the efflux pump activity of Pseudomonas aeruginosa and exerts a synergistic inhibitory effect when combined with CCCP. ATM potentiators-1 can be used for the research of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections .

Cat. No.	Product Name

HY-L924

Boronic acid/boronic ester fragment library	1,488 compounds
Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy. To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.

Boronic acid/boronic ester fragment library

1,488 compounds

Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy.

To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.

β-Sitosterol acetate, 95% Sitosteryl acetate, 95%	Biochemical Assay Reagents
β-Sitosterol acetate, 95% (Sitosteryl acetate, 95%) is a sterol that can be isolated from Hechtia glomerata Zucc., which has antibacterial activity and has a MIC value of 100µg/mL against carbapenem-resistant Acinetobacter baumannii .

Cat. No.	Product Name	Target	Research Area